This resource is a video abstract of a research paper created by …
This resource is a video abstract of a research paper created by Research Square on behalf of its authors. It provides a synopsis that's easy to understand, and can be used to introduce the topics it covers to students, researchers, and the general public. The video's transcript is also provided in full, with a portion provided below for preview:
"Prostate cancer that has spread to bone doesn’t completely respond to the standard androgen- targeting therapies. Rather, it tends to progress into castration-resistant prostate cancer (CRPC), which is fatal. The extracellular matrix protein tenascin-C (TNC) facilitates bone metastasis of prostate cancer, and the androgen receptor variant-AR-V7 is associated with treatment-resistant CRPC, but the potential interactions between these proteins remain unclear. To learn more, a new study examined TNC signaling and AR-V7 regulation in 3D tissue cultures called organoids. In the organoids, the interaction of prostate cancer cells with bone precursor cells (preosteoblasts) upregulated both TNC and AR-V7 expression, and this effect was enhanced by the anti-androgen drug enzalutamide. Further experiments on prostate cancer cells revealed that TNC regulates AR-V7 splicing, protein stability, and nuclear localization by activating the Src signaling pathway..."
The rest of the transcript, along with a link to the research itself, is available on the resource itself.
This resource is a video abstract of a research paper created by …
This resource is a video abstract of a research paper created by Research Square on behalf of its authors. It provides a synopsis that's easy to understand, and can be used to introduce the topics it covers to students, researchers, and the general public. The video's transcript is also provided in full, with a portion provided below for preview:
"In 2020, approximately 191,930 people were diagnosed with prostate cancer, and an estimated 33,330 people died from the disease. The most common therapies for prostate cancer involve androgen depletion via castration and/or drug treatment. However, the relapse and mortality rates of prostate cancer remain high, prompting a need for less invasive treatments. Now, a growing number of studies suggest that prostate cancer can be inhibited by the hormone melatonin. Melatonin, which is normally associated with the regulation of sleep, can inhibit prostate cancer partly by keeping androgen receptors out of cell nuclei, thus preventing excess androgen signaling and by activating MT1 signaling, ultimately reducing levels of the prostate cancer marker prostate-specific antigen. Melatonin also reduces tumor blood vessel growth and it regulates metabolism, affects differentiation, and induces death in prostate cancer cells..."
The rest of the transcript, along with a link to the research itself, is available on the resource itself.
No restrictions on your remixing, redistributing, or making derivative works. Give credit to the author, as required.
Your remixing, redistributing, or making derivatives works comes with some restrictions, including how it is shared.
Your redistributing comes with some restrictions. Do not remix or make derivative works.
Most restrictive license type. Prohibits most uses, sharing, and any changes.
Copyrighted materials, available under Fair Use and the TEACH Act for US-based educators, or other custom arrangements. Go to the resource provider to see their individual restrictions.
